Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs

BACKGROUND: Glioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH clinical collection (NCC) that includes 446 FDA-approved drugs, with the goal of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Pengfei, Mukthavavam, Rajesh, Chao, Ying, Bharati, Ila Sri, Fogal, Valentina, Pastorino, Sandra, Cong, Xiuli, Nomura, Natsuko, Gallagher, Matt, Abbasi, Taher, Vali, Shireen, Pingle, Sandeep C, Makale, Milan, Kesari, Santosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898565/
https://www.ncbi.nlm.nih.gov/pubmed/24433351
http://dx.doi.org/10.1186/1479-5876-12-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898565/
https://www.ncbi.nlm.nih.gov/pubmed/24433351
http://dx.doi.org/10.1186/1479-5876-12-13

Ejemplares similares